Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS
The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132...
Saved in:
Main Authors: | L. P. Ananyeva, M. N. Starovoytova, I. Z. Gaydukova, G. V. Lukina, E. V. Zonova, L. V. Eliseeva, G. F. Fatkhullina, D. I. Abdulganieva, D. G. Krechikova, T. V. Kropotina, O. B. Nesmeyanova, I. B. Vinogradova, E. S. Zhugrova, L. V. Ivanova, N. E. Nikulenkova, O. R. Ziganshin, T. V. Plaksina, M. V. Zlobin, Yu. Yu. Grabovetskaya, N. F. Soroka, O. B. Ershova, T. V. Povarova, O. N. Anoshenkova, A. A. Lutsky, A. V. Zinkina-Orikhan, Yu. N. Linkova, E. A. Fokina, A. A. Porozova, A. V. Eremeeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2025-02-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1700 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS
by: L. P. Ananyeva, et al.
Published: (2025-05-01) -
Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2024-08-01) -
Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2020-11-01) -
Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2021-03-01) -
Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial
by: Sh. Erdes, et al.
Published: (2019-12-01)